Information Provided By: 
Fly News Breaks for March 23, 2017
RARE
Mar 23, 2017 | 05:47 EDT
Citi analyst Yigal Nochomovitz lowered his price target for Ultragenyx Pharmaceutical to $56 and reiterates a Sell rating on the shares following news that the company's Phase 2 trial testing the medical oil triheptanoin failed to meet the primary endpoint in reducing seizure rates. A fundamental reassessment of triheptanoin is necessary, Nochomovitz tells investors in a research note. He calls himself the lone bear on Ultragenyx for the past one-and-a-half years. Piper Jaffray last night downgraded the stock to Neutral.
News For RARE From the Last 2 Days
RARE
Apr 24, 2024 | 07:26 EDT
